Immunoglobulin genes implicated in glioma risk

Janardan P Pandey, Navtej Kaur, Sandra Costa, Julia Amorim, Rui Nabico, Paulo Linhares, Rui Vaz, Marta Viana-Pereira, and Rui M Reis

Introduction

Malignant glioma, the most common primary brain cancer, is divisible into histologic subgroups based on the specific types of glial cells involved. Despite recent advances in therapy, the prognosis for the majority of glioma patients remains grim. The most aggressive form of the disease glioblastoma multiforme is commonly lethal, with afflicted patients typically dying approximately 2 years or less, following diagnosis. Therefore, there is an urgent need of novel routes of investigation in glioma research that might lead to more efficacious therapies to treat this malignancy.

Like other complex diseases, glioma is thought to result from both genetic and environmental factors. Several genes, including some belonging to the immune system, have been implicated in glioma pathogenesis. But the putative role of a major immunity-related gene complex member, immunoglobulin heavy chain γ (IGHG), has not been evaluated. Prior observations that IGHG-encoded γ marker (GM) allotypes exhibit differential sensitivity to an immunoevasion strategy of cytomegalovirus, a pathogen implicated as a promoter of gliomagenesis, has lead us to hypothesize that these determinants are risk factors for glioma. To test this hypothesis, we genotyped the IGHG loci on chromosome 14, has not been evaluated. There is a strong immunogenetic rationale for investigating the role of GM allotypes in the etiopathogenesis of glioma considering that these determinants modulate an immunoevasion strategy of human cytomegalovirus (HCMV), a common herpes virus that is thought to be an active promoter or oncological modulator of gliomagenesis. In a previous study, we showed that an HCMV-encoded Fcγ receptor (FcyR), employed by the virus to evade the effector consequences of anti-HCMV antibody binding, has differential affinity for IgG1 proteins expressing distinct GM alleles. Specifically, the HCMV FcγR encoded by the viral TRL1/IRL1 gene has significantly higher affinity for IgG1 proteins expressing the GM 3+,1-,2- allotypes than for those expressing the allelic GM 17+ allotypes. These observations led us to hypothesize that these GM alleles might represent risk or protective factors, respectively, for the development of HCMV-induced glioma. In the present work,
we applied a case-control design to test the hypothesis that subjects expressing the GM 3 allele would be at higher risk of developing glioma.

**Results**

The demographics of our study population, including patient clinicopathologic features, are described in Table 1. Results of multivariate regression analysis to assess associations between GM genotypes or allele frequencies and glioma risk among the various histologic subgroups are presented in Table 2. In comparison to subjects who were homozygous for the GM 17 allele, the GM 3 homozygotes were over twice as likely (OR = 2.82, CI 1.05–7.59), and the GM 3/17 heterozygotes were over three times as likely (OR = 3.13, CI 1.15–8.52), to develop glioma, irrespective of disease subtype (all grades). Similarly, in comparison to GM 3/3+3/17 (i.e. GM 3-carriers) genotypes to the GM 17/17 genotypes, the presence of the GM 3 allele conferred a significantly increased risk for glioma (OR = 2.95, CI 1.13–7.73) and high-grade astrocytoma (OR = 3.11, CI 1.01–9.62). Similar results were obtained when assessing the allele frequencies. It was shown that the GM 3 allele was a risk factor for glioma (OR = 1.52, CI 1.05–2.11) and high-grade astrocytoma (OR = 1.49, CI 1.03–2.15), when compared with the reference GM 17 variant. No significant associations were found between GM genotypes or GM alleles and the risk of oligodendroglioma.

We also applied a multivariate Cox proportional hazard model (adjusted for patient age and sex) to investigate the association between GM polymorphism and overall survival. Glioblastoma patients for which follow up information was available who carried the GM 17/17 genotype (n = 4, 2 deaths) had a longer median overall survival than patients carrying the GM 3/17 (n = 18, 14 deaths) or GM 3/3 (n = 23, 17 deaths) genotypes with a median survival of 35 mo (range, 2–38) versus 16 mo (range, 3–52), respectively. However, the difference was not statistically significant (HR = 2.78; 95% CI, 0.61–12.65, \( P = 0.19 \)), probably due to limited sample size in analysis (Fig. 1). (The survival curves for the three genotypes separately are presented in Figure S1.)

**Table 1.** Clinicopathologic features of gliomas and controls

| Groups (WHO grade)       | N     | Age years (mean ± SD) | Male/female ratio |
|--------------------------|-------|-----------------------|-------------------|
| Controls                 | 133   | 36–85 (54.80± 9.39)   | 1.6               |
| Glioma (all grades)      | 120   | 20–83 (56.38 ± 12.55) | 1.6               |
| Astrocytoma (all grades) | 97    | 22–83 (57.55 ± 12.21) | 1.9               |
| Oligodendroglioma (all grades) | 23 | 20–78 (51.48 ± 13.08) | 0.8               |
| Astrocytoma (grades II-IV) | 95  | 22–83 (57.67 ± 12.04) | 1.9               |
| Astrocytoma (grades III-IV) | 90  | 22–83 (58.21 ± 11.80) | 2.0               |

**Table 2.** Multivariate logistic regression analysis of associations between GM variants and risk of glioma

| Genotypes* | Control | Glioma (All Grades) | OR (95% CI)\(^1\) | Astrocytoma (Grades III-IV) | OR (95% CI)\(^1\) | Oligodendroglioma (All Grades) | OR (95% CI)\(^1\) |
|------------|---------|---------------------|-------------------|-----------------------------|-------------------|--------------------------------|-------------------|
| GM 17/17   | 18      | 6                   | -                 | 4                           | -                 | 2                              |                   |
| GM 3/3     | 64      | 61                  | 2.82 (1.05–7.59)  | 2.91 (0.91–9.28)            | 10                | 1.67 (0.32–8.53) \( P = 0.55 \) |
| GM 3/17    | 51      | 53                  | 3.13 (1.15–8.52)  | 3.37 (1.05–10.87)           | 11                | 2.09 (0.41–10.61) \( P = 0.37 \) |
| GM 3/3+3/17| 115     | 114                 | 2.95 (1.13–7.73)  | 3.11 (1.01–9.62)            | 21                | 1.86 (0.39–8.88) \( P = 0.43 \) |
| Alleles**  | 133     | 120                 | 90                | 23                          |                   |                                 |                   |
| 17         | 0.327   | 0.271               | -                 | 0.267                       | -                 | 0.326                          |                   |
| 3          | 0.673   | 0.729               | 1.52 (1.10–2.11)  | 0.733                       | 1.49 (1.03–2.15)  | 0.674                          | 1.15 (0.65–2.05)  |

Significance of associations between GM genotypes or alleles and risk of glioma in various histologic subgroups. *Reference genotype GM 17/17; **Reference allele 17; regression models included age and sex as covariates.\( OR (95\% CI)—Odds ratio with 95% confidence intervals.\)

©2014 Landes Bioscience. Do not distribute.
Results presented here show that carriers of the GM 3 allele of IgG1 have 3-fold higher risk of high-grade glioma than non-carriers. Potential underlying mechanisms could involve a direct contribution of GM alleles to immunity to self and non-self antigens relevant to gliomagenesis. Alternatively, it is possible that there may be another locus affecting glioma susceptibility that is distinct from GM on chromosome 14 and whose alleles are in significant linkage disequilibrium with those of the GM loci. This putative linkage disequilibrium could give rise to the associations observed. The most relevant among the self-antigens, immunity to which is influenced by GM alleles, are human epidermal growth factor receptor 1 (HER1/EGFR) and HER2. These tumor-associated antigens are aberrantly expressed in gliomas19,20 and we have previously shown that GM alleles epistatically interact with FcγRIIIa alleles expressed on natural killer cells and mediate antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing cancer cells.21 Though not yet investigated in glioma, antibody responses to HER2 are significantly associated with GM alleles in patients with breast cancer.16,22,23 This may hold for patients with glioma as well.

The most relevant among the non-self factors, immunity to which is influenced by GM alleles, is HCMV. As mentioned before, the current consensus in the glioma field is that HCMV is an active promoter or oncogenic modulator of gliomagenesis, not merely a bystander.16 GM alleles could influence HCMV-glioma association by influencing antibody responsiveness to viral epitopes and further by modulating the viral immunoevasion strategies. In the inflammatory autoimmune disease scleroderma (systemic sclerosis), HCMV appears to accelerate the development of disparate disease pathologies24-26 and, of particular importance, we have found a highly significant association between anti-HCMV IgG antibody responses and the GM 3 and GM 17 alleles expressed on IgG1 in these patients.27 Similar studies evaluating correlations between the presence of particular GM allelic variants and HCMV antibodies should be conducted for glioma patients.

GM allotypes are expressed in the constant region of γ chains. How could these constant-region determinants influence immune responsiveness thought to be exclusively associated with the variable-region genes? Recent investigations have challenged this central tenet of immunology. Several studies have shown that structural variation in the constant region affects the expression of certain idiotypes and causes variation in the specificity of variable-region-identical immunoglobulin molecules.28 It is especially noteworthy that amino acid sequence polymorphism in the CH1 domain of the γ1 chain—where the allelic determinants GM 3 and GM 17 are located—has been shown to modulate the kinetic competence of antigen binding sites.29 Thus, amino acid substitutions associated with GM allotypes cause structural changes in the constant region, which could translate to structural constraints (conformation) imposed on the variable region, resulting in variation in antibody specificity and affinity.

As mentioned above, GM alleles modulate one of HCMV’s immunoevasion strategies. The HCMV TRL11/IRL11-encoded FcγR—which enables the virus to evade the effector consequences of antibody binding, such as antibody-dependent cellular cytotoxicity, complement-dependent neutralization, and phagocytosis—discriminates between IgG1 proteins expressing GM 3 and GM 17 alleles. The HCMV-encoded FcγR has significantly higher affinity for IgG1 proteins expressing the GM 3+,1-,2- allotypes than for those expressing the allelic GM 3+,1+,2+ allotypes.30 It naturally follows that individuals expressing the relatively higher affinity GM 3+,1-,2- alleles would be more likely to have their Fc domains scavenged, thereby reducing their immunological competence to eliminate the virus through Fc-mediated effector mechanisms. Therefore, one would anticipate that decreased immunity against HCMV would be conducive to glioma development, such that the frequency of GM 3+,1-,2- alleles would be expected to be higher in glioma patients than in healthy controls. In fact, our findings are fully consistent with this prediction.

If GM genes are risk factors for glioma, as shown here, why have they not been detected by the genome-wide association studies (GWAS) of this malignancy?30 A likely reason underlying this deficiency may be the absence of these genes in many commonly used genotyping platforms. The IGHG gene segments harboring GM alleles are highly homologous (> 95%) and apparently not amenable to the high throughput genotyping technology used in the GWAS.
in GWAS. Furthermore, because these genes were not typed in either the HapMap or 1000 Genomes projects, they cannot be imputed or tagged via linkage disequilibrium by single nucleotide polymorphisms (SNPs) included in the genotyping platforms. This underscores the necessity for the candidate gene approach to prospectively investigate the causal role for the IGHG gene complex, particularly the GM alleles, in the immunopathology of glioma.

Future studies involving GM allotypes and disease risk may also shed light on the reasons behind the racial differences in the prevalence of glioma. Age-adjusted glioma rates are considerably higher in Caucasians than in people of African descent. In these regards, it is potentially highly relevant that the GM 3 allele, implicated in the risk of glioma in our study here, is either absent, or extremely rare, in people with unmixed African ancestry.

Future studies should also consider examining the interactive effects of particular candidate genes in gliomagenesis. Genes do not act in isolation and there is preponderant evidence that epistasis—modification of the action of one gene by the action of one, or more, other genes—plays a significant role in human disease processes. With this in mind, IGHG (GM allotypes) and HLA are excellent candidate genes for epistatic investigations in glioma, as both are targets of HCMV immunoevasion strategies and have been shown to contribute to glioma risk, GM alleles in the present investigation and HLA alleles in previous studies.

To our knowledge, this is the first report implicating GM genes in susceptibility to glioma, a devastating and often lethal malignancy. Replication, using a larger, independent cohort, is needed to validate the results presented here.

Material and Methods

Glioma patients and controls

The study population has been described in detail elsewhere. All samples with available DNA isolated from peripheral blood lymphocytes were included in this work. Briefly, 120 glioma patients were recruited at Hospital de Braga, Braga and Hospital S. João, Porto, Portugal. Controls consisted of 133 cancer-free random blood donors. Both patients and controls were Caucasians. The study protocol was approved by the Institutional Ethical Committees. Peripheral blood samples from patients and normal controls were collected after informed consent, according to the Helsinki Declaration.

Quantitative PCR-based GM genotyping

At position 214 of the γ1 chain, an arginine residue characterizes the GM 3 allele and a lysine characterizes the GM 17 allele. This corresponds to a G to A nucleotide substitution in the γ1 gene. We used a pre-designed TaqMan® genotyping assay targeting these variants from Applied Biosystems Inc., according to manufacturer’s instructions and employing the following primers and probes: forward primer (5’ CCGACAGCTA CATCTGCCAC GTGA-3’); reverse primer (5’ CTGCCCTGGGA CTTGGACTGC AT-3’); reporter 1 (GM 17-specific) (VIC-CTCTCACAA CTTTCTTGTFQ); reporter 2 (GM 3-specific) (FAM-CTCTCACAA CTCTTTTGTFQ)

Statistical analyses to evaluate associations between glioma and GM genotype

Genotype frequencies were in Hardy–Weinberg equilibrium in both groups. To evaluate the effect of an IgG1 GM variant on the risk of glioma, odds ratios (OR) and 95% confidence intervals (95% CI) were estimated by unconditional multivariate logistic regression analysis adjusted for potential confounding variables (i.e., patient age and sex). We estimated ORs of glioma risk associated with the GM 3/3 or GM 3/17 genotype relative to that of GM 1/1 used as reference. We also analyzed a model in which the combined GM 3/3+3/17 was compared with the genotype GM 1/1 (reference). Additionally, the allelic frequency of 3 and 17 alleles was estimated, as well as the ORs associated with risk of glioma. Associations between GM variants and patient survival were assessed using a multivariate Cox regression model adjusted for patient age, and sex. In this analysis, the genotypes and patient survival for GM 3/3+3/17 were compared with those of GM 1/1 patients, again used as a reference standard. Our rationale for choosing the less frequent (GM 17) allele as reference is that our hypothesis is based on the fact that people expressing the GM 3 variant have a reduced immunological competence to eliminate HCMV and, as such, have an increased risk to develop glioma. Patients were followed until death or loss to follow-up. Statistical significance was defined as P < 0.05. All reported P values are 2-sided. Data analysis was performed using SPSS 20.0 software (SPSS, Inc.).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Supplemental Materials

Supplemental materials may be found here: www.landesbioscience.com/journals/oncoimmunology/article/28609

Acknowledgments

This work was supported in part by the US. National Institute of Neurological Disorders and Stroke and by Fundação a Ciência e Tecnologia, Portugal (PTDC/SAU-ONC/115513/2009). The authors thank the Immunochemotherapy Department of Hospital S. Marcos, and Clínica Laboratorial Dr. Edgar Botelho Moniz, S. Tirso, Portugal, for their helpful assistance in the management of controls, and to Monica Ferreira from ICVS for her valuable assistance in the management of cases and controls.
References

1. Tang J, Shao W, Dorak MT, Li Y, Miike R, Lobachevsyev V, Wiencek JK, Wiencek M, Kaslow RA, Cobbs CS. Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev 2005; 14:2040-4; PMID:16103458; http://dx.doi.org/10.1158/1055-9966.EPI-05-0336

2. Song W, Ruder AM, Hu L, Li Y, Ni R, Shao W, Kaslow RA, Butler M, Tang J. Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs. PLoS One 2009; 4:e7157; PMID:19774073; http://dx.doi.org/10.1371/journal.pone.0007157

3. Schwarztbaum JA, Xiao Y, Liu Y, Tsvachidz S, Berger MS, Bondy ML, Chang JS, Chang SM, Decker PA, Ding B, et al. Inherited variation in immune genes and pathways and glioblastoma risk. Carcinogenesis 2010; 31:1770-7; PMID:20668009; http://dx.doi.org/10.1093/carcin/bqg152

4. Amri ES, Scheurer ME, Liu Y, D'Amelio AM Jr., Houlston RS, Etzel CJ, Shete S, Swerdlow AJ, Scheemaker MJ, McKinney PA, et al. A novel approach to exploring potential interactions among single-nucleotide polymorphisms of inflammation genes in glomangiosarcoma: an exploratory case-only study. Cancer Epidemiol Biomarkers Prev 2011; 20:1683-9; PMID:21724854; http://dx.doi.org/10.1158/1055-9966.EPI-2011-0120

5. Rajarajan P, Melin BS, Wang Z, McKeon-Cowdin R, Michaud DS, Wang SS, Bondy M, Houlston R, Jenkins BK, Wiencek M, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet 2012; 131:1877-88; PMID:22886559; http://dx.doi.org/10.1007/s00431-012-1212-0

6. Costa BM, Viana-Pereira M, Fernandes R, Costa S, Linhares P, Var R, Pinheiro C, Lima J, Soares P, Silva A, et al. Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiol Biomarkers Prev 2011; 20:2610-7; PMID:21960689; http://dx.doi.org/10.1158/1055-9966.EPI-11-4340

7. Lima-Ramos V, Pacheco-Figueirolo L, Costa S, Pardal F, Silva A, Amorim J, Lopes JM, Reis RM. TP53 codon 72 polymorphism in susceptibility, and prognosis of adult glioblastoma multiforme. Neuro Oncol 2012; 14:266-55; PMID:22392190; http://dx.doi.org/10.1093/neuonc/nos227

8. Namboodiri AM, Pandey JP. The human cytomegalovirus TRL11/IRL11-encoded FcRγR binds differentially to allelic variants of immunoglobulin G1. Arch Virol 2011; 156:907-10; PMID:21311920; http://dx.doi.org/10.1007/s00429-012-0907-8

9. Pandey JP, Genetic and viral etiology of glioblastoma--a unifying hypothesis. Cancer Epidemiol Biomarkers Prev 2011; 20:1061-3; PMID:21586624; http://dx.doi.org/10.1158/1055-9966.EPI-11-0247

10. Wong AJ, Ruppen JM, Bigler SH, Grzeschik CH, Humphrey PA, Bigler DS, Vogelstein B. Structural and functional characterization of the genetic and viral etiology of glioblastoma. Proc Natl Acad Sci U S A 1992; 89:2965-9; PMID:15577402; http://dx.doi.org/10.1073/pnas.89.7.2965

11. Krišt DA, Yarden Y. Differences between phosphotyrosine accumulation and Neu/ ErbB-2 receptor expression in astrocytotic proliferative processes. Implications for gliogenic oncosurveillance. Cancer 1996; 78:1272-83; PMID:8826951; http://dx.doi.org/10.1002/(SICI)1097-0248(19960915)78:6<1272::AID-CNCR163>3.0.CO;2-Y

12. Namboodiri AM, Pandey JP. Differential inhibition of trastuzumab- and cetuximab-induced cytostasis of cancer cells by immunoglobulin G1 expressing different GM alleles. Clin Exp Immunol 2011; 166:361-5; PMID:22099994; http://dx.doi.org/10.1111/j.1365-2249.2011.04775.x

13. Pandey JP, Namboodiri AM, Kurnenkov O, Nietert PJ. Genetic regulation of humoral and epidermal growth factor receptor 2 in breast cancer. Hum Immunol 2010; 71:1124-7; PMID:20736037; http://dx.doi.org/10.1016/j.humimm.2010.08.009

14. Pandey JP, Namboodiri AM, Kistner-Griffen E, Iwasaki M, Kasuga Y, Hamada GS, Tsugane S. Racially restricted contribution of immunoglobulin Fcγ and Fcε receptor genotypes to humoral immunity to human epidermal growth factor receptor 2 in breast cancer. Clin Exp Immunol 2013; 171:273-7; PMID:2373943; http://dx.doi.org/10.1111/cel.12108

15. Pandey JP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 1998; 41:10-5; PMID:9435864; http://dx.doi.org/10.1002/1529-0138(199801)41:1<10::AID-ART2.3.CO;2-P

16. Lunardi C, Bacon C, Navone R, Millo E, Damonte G, Corrocher R, Puccetti A. Systemic sclerosis. Immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000; 6:1183-6; PMID:11017512; http://dx.doi.org/10.1038/80553

17. Lunardi C, Dolcino M, Peterlana D, Bacon C, Navone R, Tamassia N, Beri R, Corrocher R, Puccetti A. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 2006; 3:2-2; PMID:16384112; http://dx.doi.org/10.1371/journal.pmed.0030022

18. Pandey JP. Immunoglobulin GM genes and IgG antibodies to cytomegalovirus in patients with systemic sclerosis. Clin Exp Rheumatol 2004; 22(Suppl 33):309-7; PMID:15344996

19. Casadevall A, Pirofski L-A. A new synthesis for antibody-mediated immunity. Nat Immunol 2012; 13:21-8; PMID:22179281; http://dx.doi.org/10.1038/ni.2184

20. Torres M, Fernández-Fuentes N, Fiser A, Casadevall A. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem 2007; 282:13917-27; PMID:17353196; http://dx.doi.org/10.1074/jbc.M700676200

21. Enciso-Mora V, Hocking FJ, Kinnersley B, Wang Y, Shete S, Zelenika D, Broderick P, Idbaih A, Delattre YJ, Hoang-Xuan K, et al. Deciphering the 8q24.21 association for glioma. Hum Mol Genet 2011; 20:2293-302; PMID:21339948; http://dx.doi.org/10.1093/hmg/ddr063

22. Moore JH. The ubiquitous nature of epitope in determining susceptibility to common human diseases. Hum Hered 2003; 56:73-82; PMID:14614241; http://dx.doi.org/10.1159/000073735

23. Phillips PC. Epistasis—the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 2008; 9:855-67; PMID:18852697; http://dx.doi.org/10.1038/ng.2452

24. Lehrer B. Molecular mechanisms of epitope variation within and between genes. Trends Genet 2011; 27:323-31; PMID:21604621; http://dx.doi.org/10.1016/j.tig.2011.05.007

25. Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Res 2011; 157:151-60; PMID:21056604; http://dx.doi.org/10.1016/j.virusres.2010.10.031

www.landesbioscience.com
Oncoimmunology

e28609-5

©2014 Landes Bioscience